

March 12, 2025

BSE Limited Listing Department- Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 544292, ISIN: INE013P01021 Scrip Code: 975645, ISIN: INE013P07028	National Stock Exchange of India Ltd Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E) Mumbai – 400 051 Symbol: ONESOURCE
--	---

Dear Madam/ Sir,

Subject: **Intimation under Regulation 30 as per SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015**

We hereby submit the disclosure regarding draft order u/s 144 C (1) issued by Assessment Unit, Income Tax Department Ministry of Finance, Government of India pertaining to AY 2022-23, wherein certain tax adjustments of INR 425.95 Mn relating to transfer pricing issues have been made. The Company will suitably challenge the order in due course.

Sl. No.	Particulars	Remarks
a)	Name of the Authority	National Faceless Assessment Centre (NFAC) – Income Tax Department
b)	Nature and details of the action(s) taken, initiated or order(s) passed	Adjustments in Transfer Pricing Order pertaining to AY 2022-23
c)	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Draft assessment order received on March 12, 2025
d)	Brief details of dispute/litigation or Details of the violation(s)/contravention(s) committed or alleged to be committed	Onesource Specialty Pharma Limited has received an Order from the NFAC under Section 144C(1) of the Income Tax Act, 1961 for Assessment Year 2022-23, wherein certain tax adjustments of INR 425.95 Mn relating to transfer pricing issues have been made.
e)	Court/tribunal/agency where the litigation is filed	The issues in the aforementioned draft order will be challenged before the Dispute Resolution Panel on/before April 11, 2025
f)	Expected financial implications, if any, due to compensation, penalty etc; Quantum of claims, if any	The tax adjustments made will be offset against the accumulated tax losses. No tax demand expected.

The above information is also available on the website of the Company i.e. <https://www.onesourcecdmo.com/investor-relations/stock-exchange-intimation/>. You are requested to kindly take the same on record.

Thanking you,

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

